TJ191 is a selective small-molecule agent designed to target and eliminate malignant T-cell leukemia/lymphoma cells characterized by low expression of TbetaRIII. Its application in both in vitro and in vivo research models supports its investigation as a potential therapeutic strategy for specific T-cell malignancies.